Joint approach of diffusion- and perfusion-weighted MRI in intra-axial mass like lesions in clinical practice simulation

Ra Gyoung Yoon¹*, Ho Sung Kim²*, Gil Sun Hong²*, Ji Eun Park², Seung Chai Jung², Sang Joon Kim², Jeong Hoon Kim³

¹ Department of Radiology, Eulji Medical Center, Eulji University College of Medicine, Seoul, Korea,
² Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea,
³ Department of Neurosurgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea

* These authors contributed equally to this work.
radhskim@gmail.com

Abstract

Although advanced magnetic resonance imaging (MRI) techniques provide useful information for the differential diagnosis of intra-axial mass-like lesions, the specific diagnostic role of multimodal MRI over conventional magnetic resonance imaging (CMRI) alone in the differential diagnosis of mass-like lesions from a large heterogeneous cohort has not been studied. In this study, we aimed to determine the added value of a joint approach of diffusion-weighted imaging (DWI) and dynamic-susceptibility-contrast perfusion imaging (DSC-PWI) for diagnosis of intra-axial mass-like lesions, comparing them with CMRI alone. Furthermore, we performed these evaluations in a manner simulating clinical practice. Our institutional review board approved this retrospective study and waived the requirement for informed consent. A total of 1038 patients with intra-axial mass-like lesions were retrospectively recruited according to their histological and clinico-radiological diagnoses made between January 2005 and December 2014. All patients underwent CMRI, DWI and DSC-PWI. The diagnostic accuracy and confidence in diagnosing each type of intra-axial mass-like lesions, and for differentiating the intra-axial brain tumors from non-neoplastic lesions, were compared according to the MRI protocols. The disease-specific sensitivity of joint approach differed according to specific disease entities in diagnosing each disease category. Joint approach provided the best diagnostic accuracy for discriminating intra-axial brain tumors from non-neoplastic lesions, with high diagnostic accuracy (95.3–96.7%), specificity (82–84.0%), positive-predictive-value (97.0–97.3%), and negative-predictive-value (84.8–92.7%), with the reader’s confidence values being significantly improved over those on CMRI alone (all p-values < 0.001). In conclusion, joint approach of DWI, DSC-PWI to CMRI helps to differentiate non-neoplastic lesions from intra-axial brain tumors, and improves diagnostic confidence compared with CMRI alone. The benefit from the combined imaging differs for each disease category; thus joint approach needs to be customized according to clinical suspicion.
Introduction

During recent decades, advanced magnetic resonance imaging (MRI) techniques, such as diffusion-weighted imaging (DWI), dynamic susceptibility contrast perfusion imaging (DSC-PWI), and magnetic resonance spectroscopy (MRS) have become available as adjuncts to conventional magnetic resonance imaging (CMRI) techniques have increased diagnostic accuracy in the differentiation of intra-axial brain tumors [1–5]. These MRI protocols can noninvasively reflect the pathophysiological characteristics of brain tumors, and have thus been incorporated into routine protocols for evaluating patients with intra-axial mass-like lesions (MLLs). Notably, DSC imaging provides hemodynamic information associated with increased microvascular density in brain tumors, inflammatory activity, and vascular compromise in inflammatory lesions [6]. DWI imaging can reflect changes in cellularity in various brain tumors, and improves the specificity of MRI for distinguishing brain abscesses and cystic tumors [7].

Although each advanced MRI technique provides useful information for the differential diagnosis of intra-axial MLLs, most previous studies have focused on the diagnostic ability of a single imaging technique [8–11], rather than comprehensive evaluation of the diagnostic value of a multimodal MRI protocol including DWI and DSC-PWI. Furthermore, many previous studies have performed quantitative analysis of separate MRI sequences and presented threshold values, whereas in clinical practice, radiologists tend to read each MRI exam through visual assessment, combining the information from various sequences. Moreover, the specified diagnostic roles of a protocol including such multiple MRI sequences in the differential diagnosis of all-encompassing inflammatory lesions such as tumefactive demyelinating lesions or abscess and tumorous conditions such as lymphoma, metastasis, or gliomas in heterogeneous cohorts have not been studied.

As a tertiary referral hospital, we have routinely applied a single-session multimodal MRI protocol, including DWI and DSC-PWI in addition to CMRI to patients with intra-axial MLLs. In this study, we sought to evaluate the diagnostic role and influence on diagnostic pattern of this joint approach of DWI and DSC-PWI compared to CMRI alone. In this evaluation, we tried to simulate clinical practice by including patients presenting with any intra-axial MLLs, thereby including a wide range of disease entities.

Materials and methods

Patient population

The protocol of this retrospective study was approved by the institutional review board of Asan Medical Center and the need for informed consent was waived [http://eirb.amc.seoul.kr]. A retrospective review of our institution’s database for the period January 2005 to December 2014 identified 4,981 patients who had undergone an MRI protocol including conventional MRI, DWI, and DSC-PWI for the evaluation of intra-axial MLLs. MLLs were defined as volumetric space-occupying lesions distinct from normal-appearing brain parenchyma on conventional MRI. The following exclusion criteria were applied patients with an extra-axial brain mass; those younger than 18 years of age; those who had undergone surgery or treatment, i.e., steroid therapy or radiation, before the MRI examination; those either a follow-up MRI for clinical diagnosis, or histologic diagnosis; and those without complete MRI protocols. Finally, 1,038 patients (mean age ± SD, 50.6 ± 14.9 years) who initially presented with intra-axial MLLs were included in our study. Among these 1038 patients, 150 were diagnosed with non-neoplastic lesions and 888 with intra-axial brain tumors. The 150 patients with non-neoplastic lesions included 116 classified as non-neoplastic other brain diseases (NOBDs; 30
demyelinating disease, 32 subacute or venous infarction, 22 encephalitis, 17 vasculitis, six traumatic contusion, one hippocampal sclerosis), 21 classified as abscess, and 13 classified as tumefactive demyelinating disease (TDL). The NOBDs were defined as non-neoplastic mass-like brain lesions other than TDL and abscess. Among the 888 patients with tumors, 92 had lymphoma, 210 had low-grade glioma (LGG), 127 had metastasis, 368 had high-grade glioma (HGG), and 91 were diagnosed with other brain tumors. The World Health Organization neoplasm grading scheme was employed for intra-axial brain tumors.

Reference standard for the final diagnosis

The final diagnosis was made from either pathologic report (surgical resection or biopsy), CSF cytology analysis (i.e. encephalitis, lymphoma), or clinico-radiologic diagnosis. For clinico-radiologic diagnosis, a follow-up MRI was used as the reference standard. For intra-axial brain tumors, the World Health Organization neoplasm grading scheme was employed in the pathologic report. In the 150 patients with non-neoplastic lesions, 51 patients were histologically confirmed, and 99 patients were clinico-radiologically diagnosed. Of these 99 patients, 32 patients with infarction were confirmed by angiography, 22 with encephalitis were confirmed by CSF analysis and a positive response to antibiotics, 17 with vasculitis were confirmed by laboratory findings and a positive response to steroid therapy, six patients with traumatic contusion were confirmed by trauma history and follow-up MRI, three patients with demyelinating disease and nine patients with TDL were confirmed by follow-up MRI and a positive response to steroid therapy, and one patient with hippocampus sclerosis was confirmed history of recurrent seizure, electroencephalography, and follow-up MRI [12]. Of the 888 patients with intra-axial brain tumors, 745 patients were histologically confirmed, and 143 patients were clinico-radiologically diagnosed. Of the 143 clinico-radiologically diagnosed patients, six with lymphoma were confirmed by cytology analysis [13,14], 51 with metastasis were confirmed by the identification of a primary neoplasm in another organ with multiple metastasis and/or additional brain metastasis on follow-up MRI [12], 64 with LGG were confirmed by MR imaging findings and long-term follow-up MRI (mean time, 1049 ± 757.4 days), and ten with HGG were confirmed by agreement between the neurosurgeon and the neuroradiologist after complete review of both the clinical information and the MR imaging findings, with no identification of malignancy in other organs during the follow-up period (mean time, 314.7 ± 140.7 days). The remaining 12 patients with other brain tumors were diagnosed by long-term follow-up MRI after exclusion of the aforementioned brain tumors (mean time, 1194.3 ± 1026.3 days).

Imaging technique

CMRI, DWI, and DSC-PWI were performed using a 3T system (Achieva; Philips Medical Systems, Best, The Netherlands) with an eight-channel, sensitivity-encoding head coil. The imaging protocol was acquired in the following order: T2-weighted imaging, DWI, T1-weighted imaging, gadolinium-enhanced T1-weighted imaging, and DSC-PWI. DWI was acquired in three orthogonal directions and combined into a trace image. Using this data, i.e. b-values of 0 and 1000 s/mm2 on a voxel-by-voxel basis, the software incorporated into the MR imaging unit calculated the apparent diffusion coefficient (ADC) map. The DWI parameters were as follows: repetition time (TR)/echo time (TE), 3000/56 ms; field of view (FOV), 25 cm; slice thickness/gap, 5 mm/2 mm; matrix, 256 x 256; diffusion gradient encoding, b = 0, and 1000 s/mm2; and acquisition time, 39 seconds. DSC-PWI was performed using a gradient-echo, echo-planar sequence during which a standard dose of 0.1 mmol/kg of gadoterate meglumine (Dotarem; Guerbet, Paris, France) was administered at a rate of 4 mL/s using an MR-imaging-
compatible power injector (Spectris; Medrad, Pittsburgh, PA, USA). The bolus of contrast material was followed by a 20-mL bolus of saline administered at the same injection rate. The imaging parameters for DSC-PWI were as follows: TR/TE, 1808/40 ms; FOV, 24 cm; slice thickness/gap, 5 mm/2 mm; matrix, 128 x 128; and flip angle, 35°. The total acquisition time for DSC-PWI was 114 seconds. DSC-PWI was performed using the same section orientations as the CMRI, and covered the entire tumor volume.

**Imaging analysis**

Two expert radiologists (G.S.H. and R.G.Y. with 7 and 6 years of clinical experience in brain MRI, respectively) who were blinded to the patients’ diagnosis and other clinical information, independently performed visual, semi-quantitative assessment in three reading sessions separated by an interval of over a month so as to avoid recall bias. The readers interpreted only the CMRI protocol (i.e., T2-weighted images, T1-weighted images, and gadolinium-enhanced T1-weighted images) in the first reading session, joint approach protocol of CMRI and DWI in the second reading session, and then joint approach protocol includes CMRI and DWI plus DSC-PWI in the third reading session. In each reading session, the readers interpreted all 1038 cases in a re-randomized order, suggesting up to three differential diagnoses in order of confidence from a list of the above eight disease categories, and rated their confidence level for each diagnosis using a hierarchical three-point scale: grade 3 = definite, confidence level ≥ 95%; grade 2 = probable, confidence level 70–95%; and grade 1 = possible, less than 70% confidence [15,16]. For semi-quantitative visual assessment, the ADC values were classified according to a four-point scale: ADC value < white matter (Grade 4); ADC value = white matter (Grade 3); CSF < ADC value < white matter (Grade 2); and ADC value = CSF (Grade 1) [17–19]. The following four-point grading system was used for DSC-PWI: perfusion value = vessel (Grade 4); gray matter < perfusion < vessel (Grade 3); perfusion = gray matter (Grade 2); and perfusion < gray matter (Grade 1). All MR images were assessed using a local PACS monitor and digital imaging and communications in medicine (DICOM) image viewing software (PetaVision: Asan Medical Center, Seoul, Korea).

**Analysis of diagnostic confidence**

The readers’ diagnostic confidence was determined qualitatively according to a combination of confidence score from at least one to three for each differential diagnoses, and the number of diagnoses made for each case. The highest reader confidence was considering one diagnosis with grade 3 confidence, and the lowest reader confidence was considering three differential diagnoses with all grade 3 confidence. The reader confidence was scored from 1 to 9 points with 9 being the highest score as follows: 1 point = three differential diagnoses all with grade 3 confidence; 2 points = three differential diagnoses two with grade 3 and one with grade 2 confidence; 3 points = three differential diagnoses, two with grade 3 and one with grade 1 confidence; 4 points = two differential diagnoses, both with grade 3 confidence; 5 points = three differential diagnoses, one with grade 3 and two with grade 2 confidence; 6 points = three differential diagnoses, one with grade 3, one with grade 2, and one with grade 1 confidence; 7 points = two differential diagnoses, one with grade 3 and one with grade 2 confidence; 8 points = two differential diagnoses, one with grade 3 and one with grade 1 confidence; and 9 points = one diagnosis with grade 3 confidence. The diagnostic confidence values are illustrated using the heat maps [20–22].

**Statistical analysis**

The overall diagnostic accuracies of the three MRI protocol sets for all intra-axial MLLs were compared using logistic regression. A decision threshold of grade 3 was considered positive,
and the diagnostic accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for the discrimination of neoplastic lesions from non-neoplastic lesions, and the per-disease sensitivity and PPV for diagnosis of each disease entity, were compared between the three MRI protocols using logistic regression with generalized estimating equations. The generalized estimating equation models by eight diseases with a diagnostic value of Yes or No for each disease as the dependent variable, and the (CMRI vs CMRI and DWI vs. CMRI and DWI and DSC-PWI) as independent variables. The correlation structure was treated as an exchangeable working correlation structure. The diagnostic confidence values for diagnosis of intra-axial MLLs were compared between MRI protocols using a paired t-test. The complete data on diagnostic confidence are presented using heat maps [17, 18, 20]. Interobserver agreements in diagnosing intra-axial MLLs were measured using kappa statistics. A p-value < 0.05 was considered statistically significant for overall comparisons between the imaging protocol sets.

Results

Summary of patient characteristics and clinical information

Of the 1038 patients, 150 were diagnosed with non-neoplastic lesions and 888 with intra-axial brain tumors. The demographic characteristics and clinical information of the study patients are summarized in Table 1.

Added value of joint approach MRI protocols for discriminating neoplasms from non-neoplastic lesions

Joint approach of CMRI with DWI plus DSC-PWI improved overall diagnostic accuracy in comparison with CMRI alone (84.3% versus 80.0% for reader 1, 82.7% versus 78.0% for reader 2) (all p-values < 0.001). Compared with CMRI alone, joint approach showed increased accuracy (96.7% for reader 1, 95.3% for reader 2), specificity (84.0% for reader 1, 82.0% for reader 2), PPV (97.3% for reader 1, 97.0% for reader 2) and NPV (92.7% for reader 1, 84.8% for reader 2) in the discrimination of neoplasms from non-neoplastic lesions. Of particular note is that the joint approach increased specificity by 10.7% for reader 1 and 9.3% for reader 2. Reader 2 showed slightly decreased sensitivity using the joint approach (97.5%) in comparison with

Table 1. Patient characteristics and clinical information for All intra-axial mass-like lesions.

| Characteristics                  | All patients | Non-neoplastic lesions | Neoplasms |
|----------------------------------|--------------|------------------------|-----------|
| No. of patients                  | 1038         | 116                    | 21        |
| Sex (M/F)                        | 591/447      | 64/52                  | 16/5      |
| Age, years (Mean±SD)             | 50.6±14.9    | 48.8±15.7              | 55.9±12.5 |
| Surgery or biopsy                | 796          | 26                     | 21        |
| Interval between MRI and surgery in days* | 17.0±27.4(0–261) | 43.3±79.8 (0–261) | 5.0±4.8 (0–18) |
| Clinicoradiologic diagnosis      | 242          | 90                     | 0         |
| Interval between initial and follow-up MRIs in days* | 630.1±666.1 (18–4042) | 529.5±546.7 (18–2618) | 0886.8±679.3 (366–2294) |

NOBDs = non-neoplastic other brain disease; TDL = tumefactive demyelinating lesion; LGG = low-grade glioma; HGG = high-grade glioma; OBT = other brain tumor; MRI = magnetic resonance imaging; SD = standard deviation.

* Data are mean ± standard deviation with range in parentheses.

https://doi.org/10.1371/journal.pone.0202891.t001
CMRI alone (97.8%). The kappa values between the two readers were 0.716–0.749 for CMRI alone and 0.781–0.801 for joint approach. Table 2 summarizes the differences in diagnostic performance between the joint approach protocol and CMRI alone for the discrimination of neoplastic from non-neoplastic lesions.

Comparison of disease-specific sensitivities and PPVs

The disease-specific sensitivity, PPV and inter-observer agreement for the diagnosis of intra-axial MLLs are shown in Table 3 for the combined protocol and CMRI alone. For diagnosis of NOBDs, the joint approach significantly improved disease-specific sensitivity in comparison with CMRI alone (from 66.4% to 78.5% for reader 1, from 64.7% to 76.7% for reader 2, p-value = 0.003 and 0.008, respectively). For diagnosis of brain abscess, the joint approach protocols significantly improved sensitivity (from 66.7% to 100%) and PPV for reader 2 (from 82.4% to 91.3% for reader 1, from 73.7% to 91.3% for reader 2, p-value = 0.064 and 0.006, respectively). However, for TDL, the sensitivity of joint approach did not differ significantly from CMRI alone for either readers (p-value = 0.717 and 1, respectively), and the PPV decreased for reader 1 (from 91.7% to 68.8%, p-value = 0.275). In the diagnosis of intra-axial brain tumors, the joint approach showed higher sensitivity and PPV for lymphoma (81.5% to 87.0%, and 84.3% to 86% for reader 1, 75% to 89.1% and 80.2% to 89.1% for reader 2, p-value = 0.001 and 0.168 for sensitivity, p-value = 0.675 and 0.009 for PPV, respectively), metastasis (89% to 89.8% and 76.9% to 77% for reader 1 and 87.4% to 89.8% and 67.3% to 74% for reader 2, p-value = 0.077 and 0.382 for sensitivity, p-value = 0.108 and 0.008 for PPV, respectively), and HGG (87.5% to 85.9% and 85.9% to 86.3% for reader 1, 84% to 85.3% and 86.1% to 87.2% for reader 2, p-value = 0.133 and 0.139 for sensitivity, p-value = 0.310 and 0.598 for PPV). In addition, the joint approach showed higher sensitivity for LGG (77.1% to 83.3% for reader 1, p-value = 0.012). For the diagnosis of other brain tumors, the joint approach showed significantly improved sensitivity and PPV (64.8% to 73.6% and 72.0% to 85.9% for reader 1, 56.0% to 74.7% and 67.1% to 87.2% for reader 2, p-value = 0.021 and < 0.001 for sensitivity, p-value < 0.001 for PPV, respectively).

Diagnostic confidence in discrimination of non-neoplastic lesions from neoplasms on different imaging protocols

All data concerning diagnostic confidence are summarized in Table 4 and illustrated in Fig 1. Compared with CMRI alone, the joint approach protocols significantly improved the

Table 2. Diagnostic performance of joint approach protocols and conventional MRI alone in discriminating neoplasms from non-neoplastic lesions.

| MRI Protocols | Accuracy, % (95% CI) | Sensitivity, % (95% CI) | Specificity, % (95% CI) | PPV, % (95% CI) | NPV, % (95% CI) |
|---------------|----------------------|------------------------|------------------------|----------------|----------------|
| MRI alone     |                      |                        |                        |                |                |
| -Reader 1     | 95.0 (93.5–96.2)     | 98.7 (97.7–99.2)       | 73.3 (65.7–79.8)       | 95.6 (94.1–96.8) | 90.2 (83.6–94.3) |
| -Reader 2     | 94.1 (92.5–95.4)     | 97.8 (96.6–98.5)       | 72.7 (65.0–79.2)       | 95.5 (93.9–96.7) | 84.5 (77.3–89.7) |
| Joint approach of C+D |           |                        |                        |                |                |
| -Reader 1     | 95.9 (94.5–96.9)     | 98.6 (97.7–99.2)       | 79.3 (72.2–85.0)       | 96.5 (95.2–97.6) | 90.8 (84.7–94.7) |
| -Reader 2     | 94.9 (93.4–96.1)     | 97.3 (96.0–98.2)       | 80.7 (73.6–86.2)       | 96.8 (95.4–97.7) | 83.5 (76.6–88.6) |
| Joint approach of C+D+P |     |                        |                        |                |                |
| -Reader 1     | 96.7 (95.5–97.7)     | 98.9 (97.9–99.4)       | 84.0 (77.3–89.0)       | 97.3 (96.1–98.2) | 92.7 (87.0–96.0) |
| -Reader 2     | 95.3 (93.8–96.4)     | 97.5 (96.3–98.4)       | 82.0 (75.1–87.3)       | 97.0 (95.6–97.9) | 84.8 (78.1–89.8) |

CMRI = conventional magnetic resonance imaging; C, conventional magnetic resonance imaging; D, diffusion-weighted imaging; P, dynamic susceptibility contrast perfusion imaging

https://doi.org/10.1371/journal.pone.0202891.t002
confidence of all readers for diagnosing non-neoplastic lesions (p-values < 0.001), and intra-axial brain tumors (p-values < 0.001). In comparison with those from CMRI, the combined approach heat maps demonstrated an increase in the areas representing higher confidence levels (i.e., dark red color) for the diagnosis of non-neoplastic lesions and intra-axial brain tumors, and a decrease in the areas representing lower confidence levels (i.e., light red and yellow colors).

Table 3. Comparison of disease-specific sensitivity and PPV between the joint approach protocols and conventional MRI alone.

| MRI protocols | Non-neoplastic Lesions | Neoplasms |
|---------------|------------------------|-----------|
|               | NOBDs | Abscess | TDL | Lymphoma | LGG | Metastasis | HGG | OBT |
| CMRI alone    |       |         |     |          |     |            |     |     |
| Sen, %        | 66.4  | 64.7    | 66.7| 84.6     | 61.5| 81.5       | 75.0| 80.0 |
| PPV, %        | 89.5  | 85.2    | 82.4| 83.8     | 42.1| 84.3       | 80.2| 88.0 |
| k, [SE]       | 0.701 [0.058] | 0.830 [0.109] | 0.388 [0.218] | 0.603 [0.089] | 0.674 [0.056] | 0.773 [0.080] | 0.738 [0.047] | 0.623 [0.071] |
| Joint approach of C + D |       |         |     |          |     |            |     |     |
| Sen, %        | 70.7  | 74.1    | 100 | 84.6     | 69.2| 87.0       | 83.7| 79.5 |
| PPV, %        | 91.1  | 83.5    | 80.8| 82.9     | 79.9| 73.2       | 72.2| 84.3 |
| k, [SE]       | 0.750 [0.060] | *     | 0.618 [0.232] | 0.762 [0.093] | 0.837 [0.044] | 0.665 [0.089] | 0.751 [0.042] | 0.743 [0.065] |
| Joint approach of C + D + P |       |         |     |          |     |            |     |     |
| Sen, %        | 78.5† | 76.7†   | 100 †| 100 †    | 84.6| 87.0       | 89.1†| 77.1 |
| PPV, %        | 93.8  | 80.9    | 91.3| 86.0     | 89.1†| 83.7      | 80.2†| 77.0 |
| k, [SE]       | 0.720 [0.072] | *     | 0.422 [0.206] | 0.864 [0.074] | 0.704 [0.058] | 0.804 [0.082] | 0.802 [0.042] | 0.704 [0.074] |

* kappa value is not available because of the 100% inter-observer agreement
† Statistically significant with a p-value less than 0.05.

CMRI = conventional magnetic resonance imaging; Joint approach = combination of CMRI, diffusion-weighted imaging, and dynamic susceptibility contrast magnetic resonance perfusion imaging; NOBDs = non-neoplastic other brain diseases; TDL = tumefactive demyelinating lesion; LGG = low-grade glioma; HGG = high-grade glioma; MLL = mass-like lesions; Sen = sensitivity; PPV = positive predictive value. Logistic regression using generalized estimating equations was used for the between protocol comparisons of the disease-specific sensitivity and PPV.

https://doi.org/10.1371/journal.pone.0202891.t003

Table 4. Readers’ confidence ratings for the different imaging protocols.

| Grade | Non-neoplastic Lesions | Neoplasms |
|-------|------------------------|-----------|
|       | R1 (p value < 0.001) | R2 (p value < 0.001) | R1 (p value < 0.001) | R2 (p value < 0.001) |
|       | C | C+D | C+D+P | C | C+D | C+D+P | C | C+D | C+D+P |
| 3     | 24 | 76  | 104   | 52 | 89  | 97    | 387 | 567 | 664   |
| 31.   | 6  | 3   | 1     | 6  | 5   |       | 537 | 577 | 671   |
| 32.   | 41 | 51  | 39    | 51 | 30  | 34    | 264 | 237 | 175   |
| 33.   | 43 | 19  | 7     | 23 | 27  | 17    | 187 | 80  | 49    |
| 321   | 6  | 8   | 1     | 1  | 8   | 4     | 6   | 14  | 1     |
| 322   | 1  | 5   | 7     | 17 | 5   | 1     |
| 331   | 1  | 1   | 1     | 1  | 1   |       |
| 332   | 13 | 8   | 1     | 18 | 18  | 4     |
| 333   | 13 | 1   | 2     | 11 | 9   | 2     |

R1, reader 1; R2, reader 2; C, conventional magnetic resonance imaging; D, diffusion-weighted imaging; P, dynamic susceptibility contrast magnetic resonance perfusion imaging

https://doi.org/10.1371/journal.pone.0202891.t004
Discussion

In this study, we evaluated the added value of joint approach of DWI and DSC-PWI over CMRI alone for diagnosing intra-axial MLLs at initial presentation, performing the image interpretation in a manner simulating clinical practice. We included a large number of patients.
diagnosed with various intra-axial MLLs and attempted to simulate the diagnostic approach used in clinical practice by recording differential diagnosis lists in order of confidence. The joint approach protocols of CMRI with DWI and DWI plus DSC-PWI improved specificity for differentiation of non-neoplastic lesion from intra-axial brain tumors, with a significant improvement in the diagnostic confidence of the expert readers. However, the impact of the joint approach was not uniform, but differed according to the specific disease. For intra-axial brain tumors, the joint approach protocol improved sensitivity and PPVs for all tumors except low grade glioma, and showed the most improvement for lymphoma. For non-neoplastic lesions, joint approach significantly improved the differentiation of abscess and NOBDs, achieving 100% sensitivity for abscesses. However, for TDLs, both the sensitivity and PPV were lower with the joint approach protocols than with CMRI, and the kappa value was the lowest among the MLLs. Thus, our findings support the clinical use of joint approach of DWI and DSC-PWI in patients with intra-axial MLLs, indicating that it has added value for differentiating non-neoplastic lesions and for narrowing-down specific disease entities. However, considering the modest improvement in diagnostic accuracy achieved with the joint approach, we consider that the added value of these joint approach protocols over CMRI alone is perhaps insufficient to justify their standard use in initial routine evaluations of most intra-axial MLLs. CMRI alone would minimize unnecessary additional cost for the initial evaluation, and then customized combined protocols could be used for those patients requiring them. This would ensure accurate stratification of patients for needing just follow-up imaging or surgical resection or medical treatment.

A potential strength of this study is that we evaluated the actual diagnostic performance of the joint approach MRI protocols in the diagnosis of various intra-axial MLLs using a method simulating that used in clinical practice. Although there have been a number of reports seeking to define the diagnostic role of DWI or DSC MRI, they are generally concerned with only two or three disease categories [1, 11, 23–28]. This does not reproduce the actual diagnostic decision making encountered in daily clinical practice, where decisions are made between various differential diagnostic lists. Here, this study included 1038 patients who initially presented in our hospital, and we tried to determine the diagnostic role of joint approach in clinical practice using visual analysis of expert readers and recording differential lists to simulate a radiologic report. Thus, our study provides comprehensive information on the practical diagnostic performance and effect on diagnostic confidence of varying combinations of DWI, DSC-PWI added to CMRI for diagnosis of intra-axial MLLs.

In terms of diagnostic performance, we found that the added value of joint approach was improved diagnostic accuracy, sensitivity, specificity, PPV, and NPV for differentiating neoplasm from non-neoplastic lesions, while DWI provided a definite benefit for diagnosing brain abscesses and lymphoma. DWI shows high signal where the motion of water within tissue is restricted [1, 11, 26–28], and this enabled the readers to differentiate abscess and lymphoma from other MLLs according to the areas with restricted diffusion. Moreover, when joint approach of CMRI with DWI was applied, the specificity for discriminating neoplasms from non-neoplastic lesion was the highest, above that of joint approach of DWI and DSC-PWI. Therefore, considering the superior diagnostic information and relatively short acquisition time of DWI, it can be claimed that the joint approach of CMRI with DWI could be used as a routine evaluation protocol for screening of intra-axial MLL patients. However, for TDL, the joint approach reduced the PPV for reader 1 compared with CMRI alone, and there was no significant difference of diagnostic sensitivity. Although this may be related to the low incidence and nonspecific imaging characteristics of TDLs, which sometimes mimic neoplastic lesions such as glioblastoma or lymphoma [29], it may also be caused by misclassification to other disease categories by misreading of the variety of information presented on the advanced MRI sequences. Another possible explanation could be our use of semi-quantitative
visual assessment without measurement of the absolute ADC value and relative cerebral blood volume (rCBV).

For most intra-axial brain tumors, the joint approach improved sensitivity and PPV. For lymphoma, metastases, and other brain tumors, both the sensitivity and PPV increased by 4% to 9% with the addition of DWI and DSC-PWI, and for most tumors the improvements were statistically significant. However, the increases in sensitivity and PPV for LGG and HGG were only around 1%, and did not reach statistical significance. These results may imply that the information obtained from DSC-PWI could help to differentiate specific types of neoplasms, but that it would not be necessary to add DWI or DSC imaging to CMRI to make a differential diagnosis for grading of brain gliomas; for these, the infiltrative component and contrast-enhancing portion can be sufficiently assessed with conventional MRI. However, the value of quantitative assessments of ADC value and rCBV as prognostic and predictive factors is not a main subject of interest in this study, which cannot be offered with semi-quantitative visual assessment on CMRI alone [19, 30, 31].

The joint approach significantly improved the diagnostic confidence over CMRI alone in all entities of intra-axial MLLs. Furthermore, the joint approach protocols of CMRI with DWI and DWI plus DSC-PWI led to higher confidence in the diagnosis of non-neoplastic lesions and neoplasms compared with just DWI and CMRI. In clinical practice, the radiologic diagnostic approach for intra-axial MLLs is usually based on a hierarchical structure with stratification into categories of diagnostic certainty or confidence among the various diagnostic lists, contrary to a study setting in which a researcher selects one diagnosis. The higher certainty for intra-axial MLL diagnosis with the joint approach protocol could narrow the differential diagnosis and have clinical value for the next phase of decision-making and further examination choices. However, whether an improvement in diagnostic confidence will result in better clinical outcomes remains unknown.

Our study had several limitations. Its retrospective design may have introduced case selection bias, as the study population consisted of patients at a single tertiary care center who presented with intra-axial MLLs. However, in reality, it is very difficult to perform prospective studies covering the whole sequences of advanced MRI for all types of intra-axial MLLs. In addition, in clinical practice, it is not always necessary to perform a joint approach protocol to differentiate non-neoplastic intra-axial MLLs such as infection and acute infarct. Second, this study included some patients who were diagnosed on the basis of our clinico-radiological diagnosis. However, as described above, we applied strict inclusion criteria to this clinico-radiological diagnosis. As histological confirmation for most benign brain diseases is usually difficult, we included only those patients without any change suggestive of malignant transformation at long-term follow-up (mean time interval ± SD, 183.6 ± 101.1–1194.3 ± 1026.3 days) for benign tumors. Lastly, we analyzed DSC-PWI using semi-quantitative visual assessment without measurement of the absolute ADC value and rCBV. However, our intention was to simulate clinical practice, using semi-quantitative visual assessment as is common in daily practice.

In conclusion, the joint approach of combining diffusion-and perfusion-weighted MRI helps to differentiate non-neoplastic lesions from intra-axial brain tumors, and improves diagnostic confidence compared with CMRI alone. The degree of benefit differs between disease categories; therefore, a joint approach needs to be customized according to clinical suspicion for intra-axial mass-like lesions.

Supporting information
S1 File.
(XLSX)
S2 File.
(XLSX)

S3 File.
(XLSX)

S4 File.
(XLSX)

Author Contributions
Conceptualization: Ho Sung Kim.
Data curation: Gil Sun Hong, Jeong Hoon Kim.
Formal analysis: Ra Gyoung Yoon, Gil Sun Hong.
Investigation: Ra Gyoung Yoon, Ho Sung Kim, Gil Sun Hong.
Methodology: Ho Sung Kim, Gil Sun Hong.
Project administration: Ho Sung Kim.
Resources: Ho Sung Kim.
Supervision: Ho Sung Kim, Seung Chai Jung, Sang Joon Kim.
Validation: Ra Gyoung Yoon, Ho Sung Kim, Gil Sun Hong.
Visualization: Ra Gyoung Yoon.
Writing – original draft: Ra Gyoung Yoon, Gil Sun Hong.
Writing – review & editing: Ra Gyoung Yoon, Ji Eun Park.

References
1. Calli C, Kitis O, Yunten N, Yurtseven T, Islekel S, Akalin T. Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors. Eur J Radiol. 2006; 58: 394–403. https://doi.org/10.1016/j.ejrad.2005.12.032 PMID: 16527438
2. Chang SC, Lai PH, Chen WL, Weng HH, Ho JT, Wang JS, et al. Diffusion-weighted MRI features of brain abscess and cystic or necrotic brain tumors: comparison with conventional MRI. Clin Imaging. 2002; 26: 227–36. PMID: 12140151
3. De Belder FE, Oot AR, Van Hecke W, Venstermans C, Menovsky T, Van Marck V, et al. Diffusion tensor imaging provides an insight into the microstructure of meningiomas, high-grade gliomas, and peritumoral edema. J Comput Assist Tomogr. 2012; 36: 577–82. https://doi.org/10.1097/RCT.0b013e318261e913 PMID: 22992609
4. Hakyemez B, Erdogan C, Bolca N, Yildirim N, Gokalp G, Parlak M. Evaluation of different cerebral mass lesions by perfusion-weighted MR imaging. J Magn Reson Imaging. 2006; 24: 817–24. https://doi.org/10.1002/jmri.20707 PMID: 16958061
5. Liu X, Tian W, Kolar B, Yeaney GA, Qiu X, Johnson MD, et al. MR diffusion tensor and perfusion-weighted imaging in preoperative grading of supratentorial nonenhancing gliomas. Neuro Oncol. 2011; 13: 447–55. https://doi.org/10.1093/neuonc/noq197 PMID: 21297125; PMCID: PMC3064693
6. Ge Y, Law M, Johnson G, Herbert J, Babb JS, Mannon LJ, et al. Dynamic susceptibility contrast perfusion MR imaging of multiple sclerosis lesions: characterizing hemodynamic impairment and inflammatory activity. AJNR Am J Neuroradiol. 2005; 26: 1539–47. PMID: 15956527
7. Stadnik TW, Chaskis C, Michotte A, Shabana WM, van Rompaey K, Luyypaert R, et al. Diffusion-weighted MR imaging of intracerebral masses: comparison with conventional MR imaging and histologic findings. AJNR Am J Neuroradiol. 2001; 22: 969–76. PMID: 11337344
8. Kremer S, Grand S, Remy C, Esteve F, Lefournier V, Pasquier B, et al. Cerebral blood volume mapping by MR imaging in the initial evaluation of brain tumors. J Neuroradiol. 2002; 29: 105–13. PMID: 12287732
9. Lu S, Ahn D, Johnson G, Law M, Zaggag D, Grossman RI. Diffusion-tensor MR imaging of intracranial neoplasmia and associated peritumoral edema: introduction of the tumor infiltration index. Radiology. 2004; 232: 221–8. https://doi.org/10.1148/radiol.2321030653 PMID: 15220505

10. Server A, Kulbe B, Maehien J, Josefsen R, Schellhorn T, Kumar T, et al. Quantitative apparent diffusion coefficients in the characterization of brain tumors and associated peritumoral edema. Acta Radiol. 2009; 50: 682–9. https://doi.org/10.1007/0003450902933123 PMID: 1949234

11. Tsougos I, Svolos P, Kousi E, Fountas K, Theodorou K, Fezoulidis I, et al. Differentiation of glioblastoma multiforme from metastatic brain tumor using proton magnetic resonance spectroscopy, diffusion and perfusion metrics at 3 T. Cancer Imaging. 2012; 12: 423–36. https://doi.org/10.1102/1470-7330.2012.0038 PMID: 23108208; PMCID: PMC3494384

12. Al-Okaili RN, Krejza J, Woo JH, Wolf RL, O’Rourke DM, Judy KD, et al. Intraxialal brain masses: MR imaging-based diagnostic strategy—initial experience. Radiology. 2007; 243: 539–50. https://doi.org/10.1148/ radiol.2432060493 PMID: 17456876

13. Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009; 374: 1512–20. https://doi.org/10.1016/S0140-6736(09)61416-1 PMID: 19767089

14. Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010; 11: 1036–47. https://doi.org/10.1016/S1470-2045(10)70229-1 PMID: 20970380

15. Hatherill M, Hanslo M, Hawkridge T, Little F, Workman L, Mahomed H, et al. Structured approaches for the screening and diagnosis of childhood tuberculosis in a high prevalence region of South Africa. Bull World Health Organ. 2010; 88: 312–20. https://doi.org/10.2471/BLT.09.062893 PMID: 20431796; PMCID: PMC2855594

16. Reiner Bi, Knight N, Siegel EL. Radiology reporting, past, present, and future: the radiologist’s perspective. J Am Coll Radiol. 2007; 4: 313–9. https://doi.org/10.1016/j.jacr.2007.01.015 PMID: 17467614

17. Park SM, Kim HS, Jahng GH, Ryu CW, Kim SY. Combination of high-resolution susceptibility-weighted imaging and the apparent diffusion coefficient: added value to brain tumour imaging and clinical feasibility of non-contrast MRI at 3 T. Br J Radiol. 2010; 83: 466–75. https://doi.org/10.1259/bjr/34304111 PMID: 19850076; PMCID: PMC3473590

18. Seo HS, Chang KH, Na DG, Kwon BJ, Lee DH. High b-value diffusion (b = 3000 s/mm2) MR imaging in cerebral gliomas at 3T: visual and quantitative comparisons with b = 1000 s/mm2. AJNR Am J Neuroradiol. 2008; 29: 458–63. https://doi.org/10.3174/ajnr.A0842 PMID: 18065512

19. Kim HS, Kim SY. A prospective study on the added value of pulsed arterial spin-labeling and apparent diffusion coefficients in the grading of gliomas. AJNR Am J Neuroradiol. 2008; 29: 458–63. https://doi.org/10.3174/ajnr.A0842 PMID: 18065512

20. Freedman MT, Osicka T. Heat maps: an aid for data analysis and understanding of ROC CAD experiments. Acad Radiol. 2008; 15: 249–59. https://doi.org/10.1016/j.acra.2007.07.010 PMID: 18206625

21. Lee H, Kim B, Kim KJ, Seo J, Park S, Shin YG, et al. Introduction of heat map to fidelity assessment of compressed CT images. Med Phys. 2011; 38: 4667–71. https://doi.org/10.1118/1.3611046 PMID: 21928640

22. Seong NJ, Kim B, Lee S, Park HS, Kim HJ, Woo H, et al. Off-site smartphone reading of CT images for patients with inconclusive diagnoses of appendicitis from on-call radiologists. AJR Am J Roentgenol. 2011; 203: 3–9. https://doi.org/10.2214/AJR.10.11787 PMID: 22451190

23. Cha S. Update on brain tumor imaging: from anatomy to physiology. AJNR Am J Neuroradiol. 2006; 27: 475–87. PMID: 16551981

24. Hakyemez B, Erdogan C, Gokalp G, Dusak A, Parlak M. Solitary metastases and high-grade gliomas: radiological differentiation by morphometric analysis and perfusion-weighted MRI. Clin Radiol. 2010; 65: 15–20. https://doi.org/10.1016/j.crad.2009.09.005 PMID: 2010416

25. Senturk S, Oguz KK, Cila A. Dynamic contrast-enhanced susceptibility-weighted perfusion imaging of intracranial tumors: a study using a 3T MR scanner. Diagn Interv Radiol. 2009; 15: 3–12. PMID: 19263367

26. Toh CH, Castillo M, Wong AM, Wei KC, Wong HF, Ng SH, et al. Primary cerebral lymphoma and glioblastoma multiforme: differences in diffusion characteristics evaluated with diffusion tensor imaging. AJNR Am J Neuroradiol. 2008; 29: 471–5. https://doi.org/10.3174/ajnr.A0872 PMID: 18065516

27. Wang S, Kim S, Chawla S, Wolf RL, Knipp DE, Vossough A, et al. Differentiation between glioblastomas, solitary brain metastases, and primary cerebral lymphomas using diffusion tensor and dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol. 2011; 32: 507–14. https://doi.org/10.3174/ajnr.A2333 PMID: 21330399
28. Yamasaki F, Kurisu K, Satoh K, Arita K, Sugiyama K, Ohtaki M, et al. Apparent diffusion coefficient of human brain tumors at MR imaging. Radiology. 2005; 235: 985–91. https://doi.org/10.1148/radiol.2353031338 PMID: 15833979

29. Abdoli M, Freedman MS. Neuro-oncology dilemma: Tumour or tumefactive demyelinating lesion. Mult Scler Relat Disord. 2015; 4: 555–66. https://doi.org/10.1016/j.msard.2015.07.013 PMID: 26590662

30. Kim HS, Goh MJ, Kim N, Choi CG, Kim SJ, Kim JH. Which combination of MR imaging modalities is best for predicting recurrent glioblastoma? Study of diagnostic accuracy and reproducibility. Radiology. 2014; 273: 831–43. https://doi.org/10.1148/radiol.14132868 PMID: 24885857

31. Prager AJ, Martinez N, Beal K, Omuro A, Zhang Z, Young RJ. Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence. AJNR Am J Neuroradiol. 2015; 36: 877–85. https://doi.org/10.3174/ajnr.A4218 PMID: 25593202; PMCID: PMC4731220